ClinicalTrials.gg
Sign In
Not yet recruitingNCT03244072Updated Sep 15, 2026

Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery

A Phase 2/3 interventional study of Moxifloxacin and Placebo in Endophthalmitis, sponsored by Jason Ahee, M.D.. Not yet recruiting at 1 site in United States. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Jason Ahee, M.D. · Phase 2/3, Interventional, and Prevention

Phase
Phase 2/3
Study type
Interventional
Enrollment
60,000
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Study summary

Intracameral injection of 0.1% moxifloxacin solution after cataract surgery to prevent endophthalmitis

Read the detailed description

Subjects will receive either intracameral injection of 0.1% moxifloxacin solution or placebo after cataract surgery. They will be followed for one month to determine if there is a statistically significant difference in the incidence of endophthalmitis.

02

Conditions studied

  • Endophthalmitis

Browse trials for

03

In context

Endophthalmitis

65 studies on the registry are indexed under Endophthalmitis; 9 are open to participants now.

This study's planned enrollment of 60,000 is above the median of 111 across 40 interventional studies indexed under Endophthalmitis.

Browse Endophthalmitis studies →

Lead sponsor

This is the only study on the registry with Jason Ahee, M.D. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • visually significant cataracts

Exclusion criteria

Exclusion Criteria:

  • allergy to fluoroquinolones, cobalamin (B12)
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
60,000 participants (estimated)

Study arms

  • Active comparator
    Treatment group

    Intracameral injection of moxifloxacin solution after cataract surgery

    Drug: Moxifloxacin

  • Placebo comparator
    Placebo group

    Intracameral injection of placebo after cataract surgery

    Drug: Placebo

Interventions

  • DrugMoxifloxacin

    Intracameral injection

    Also known as: active

  • DrugPlacebo

    intracameral injection

    Also known as: sham

06

What researchers measure

Primary outcomes

  1. Endophthalmitis after cataract surgery

    Subjects will be followed after cataract surgery and have post-operative eye examinations to determine if infection in the eye (endophthalmitis) occurs during the study period.

    Time frame: Subjects will undergo eye examinations at one day, one week, and one month post-operatively

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2027; primary completion for Oct 2030, 40 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2017
First posted
Aug 9, 2017
StartEst.
Jun 1, 2027
Primary completionEst.
Oct 2030
CompletionEst.
Oct 2031
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03244072
Lead sponsor
Jason Ahee, M.D.
Responsible party
Jason Ahee, M.D. (Medical Director, Zion Therapeutics, LLC) — Sponsor-investigator
First posted
Aug 9, 2017
Start date
Jun 1, 2027 (estimated)
Primary completion
Oct 2030 (estimated)
Completion
Oct 2031 (estimated)
Last update
Sep 15, 2026

Study contacts

Jason Ahee, M.D.
Contact
aheejason@hotmail.com
435-862-9865
Jason Ahee, M.D.
principal investigator · Zion Therapeutics, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Moxifloxacin

Other studies in this condition

Endophthalmitis →

Start the discussion